Recursion Pharmaceuticals Inc (RXRX)
8.99
-0.17
(-1.86%)
USD |
NASDAQ |
May 28, 16:00
8.96
-0.03
(-0.33%)
After-Hours: 05:16
Recursion Pharmaceuticals Cash from Operations (Quarterly): -102.30M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -102.30M |
| December 31, 2023 | -74.08M |
| September 30, 2023 | -72.92M |
| June 30, 2023 | -67.47M |
| March 31, 2023 | -73.32M |
| December 31, 2022 | -44.75M |
| September 30, 2022 | -54.54M |
| June 30, 2022 | -61.62M |
| March 31, 2022 | 77.39M |
| Date | Value |
|---|---|
| December 31, 2021 | -61.16M |
| September 30, 2021 | -33.05M |
| June 30, 2021 | -33.65M |
| March 31, 2021 | -30.76M |
| December 31, 2020 | 8.573M |
| September 30, 2020 | -19.46M |
| June 30, 2020 | -16.70M |
| March 31, 2020 | -17.82M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-102.30M
Minimum
Mar 2024
77.39M
Maximum
Mar 2022
-39.86M
Average
-44.75M
Median
Dec 2022
Cash from Operations (Quarterly) Benchmarks
| Eli Lilly and Co | 1.166B |
| Viking Therapeutics Inc | -6.134M |
| Palatin Technologies Inc | -8.607M |
| Oragenics Inc | -3.064M |
| Actinium Pharmaceuticals Inc | -7.374M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -6.653M |
| Cash from Financing (Quarterly) | 13.90M |
| Free Cash Flow | -330.63M |
| Free Cash Flow Per Share (Quarterly) | -0.4616 |
| Free Cash Flow to Equity (Quarterly) | -108.94M |
| Free Cash Flow to Firm (Quarterly) | -108.95M |
| Free Cash Flow Yield | -16.83% |